Chiron rationalizes vaccines

Sometimes having a potentially approvable product doesn't pay. That is the decision Chiron Corp. made last week in tailoring its vaccines program to exploit its strengths and not waste resources on marketing efforts that are less likely to yield desired sales figures.

At the

Read the full 438 word article

How to gain access

Continue reading with a
two-week free trial.